首页> 外文期刊>International Journal of Reproduction, Contraception, Obstetrics and Gynecology >Randomised controlled trial to compare safety and efficacy of vaginal versus oral route of misoprostol for induction of labour in term pregnancy with unfavourable cervix
【24h】

Randomised controlled trial to compare safety and efficacy of vaginal versus oral route of misoprostol for induction of labour in term pregnancy with unfavourable cervix

机译:比较米索前列醇阴道和口服米索前列醇引致宫颈不良妊娠足月分娩的安全性和有效性的随机对照试验

获取原文
           

摘要

Background: The objective of the study was to compare safety and efficacy of vaginal versus oral route of misoprostol for induction of labour in term pregnancy. Methods: A total of 100 pregnant women with clinical indication for labour induction and poor bishops score were randomly assigned to receive vaginal or oral misoprostol. Group A received 25 μg of misoprostol vaginally (maximum up to 3 doses 4 hourly interval) and group B received 25 μg of misoprostol orally (up to 5 doses 2 hourly interval) in solution form. Maternal and fetal outcomes were compared in both groups to assess the safety and efficacy of vaginal versus oral route. Results: Fifty women received vaginal and 50 women received oral misoprostol. Average interval from induction to active stage was shorter in oral misoprostol (7.42±4.2 hours versus 10.30±5.1 hours) (p=0.006). There was no significant difference (p=0.272) in the average interval from induction to delivery between the vaginal group (14.42±5.01hrs) and oral group (13.14±5.5 hrs). No significant difference in caesarean section rates (p=0.42). Incidence of hyperstimulation was significantly higher (p=0.025) in vaginal group as compared to oral group (18 % vs 4 %). Incidence of nausea, vomiting, vaginal or cervical tears and postpartum hemorrhage were comparable in both the groups. There were no statistically significant differences in neonatal outcomes. Conclusions: Oral misoprostol has a better safety profile than vaginal route as the incidence of hyperstimulation and tachysystole was significantly more in vaginal group, although there were no significant differences in the maternal and neonatal outcomes.
机译:背景:本研究的目的是比较米索前列醇阴道和口服口服米索前列醇引诱足月妊娠的安全性和有效性。方法:将100名具有引产临床指征且主教评分低的孕妇随机分配至接受阴道或口服米索前列醇治疗。 A组阴道接受25μg米索前列醇(最多3剂,每4小时间隔一次),B组口服接受25μg米索前列醇(溶液,最多5剂,每2小时间隔一次)。比较两组的母亲和胎儿结局,以评估阴道和口服途径的安全性和有效性。结果:50名妇女接受阴道治疗,50名妇女接受口服米索前列醇。口服米索前列醇从诱导到活动期的平均间隔较短(7.42±4.2小时对10.30±5.1小时)(p = 0.006)。阴道组(14.42±5.01hrs)和口服组(13.14±5.5hrs)之间从诱导到分娩的平均间隔无显着差异(p = 0.272)。剖宫产率无显着差异(p = 0.42)。与口服组相比,阴道组过度刺激的发生率明显更高(p = 0.025)(18%vs 4%)。两组的恶心,呕吐,阴道或宫颈流泪和产后出血的发生率相当。新生儿结局无统计学差异。结论:口服米索前列醇比阴道途径具有更好的安全性,因为阴道组的过度刺激和心动过速的发生率明显更高,尽管母体和新生儿结局无显着差异。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号